{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:11:19Z","timestamp":1791465079727,"version":"4.3.4"},"reference-count":154,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013254","name":"National College Students Innovation and Entrepreneurship Training Program","doi-asserted-by":"publisher","award":["X202510413104"],"award-info":[{"award-number":["X202510413104"]}],"id":[{"id":"10.13039\/501100013254","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.critrevonc.2025.105111","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T07:39:41Z","timestamp":1767339581000},"page":"105111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Research progress on immunotherapeutics for triple-negative breast cancer from a single-cell perspective"],"prefix":"10.1016","volume":"218","author":[{"given":"Zixuan","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.critrevonc.2025.105111_bib1","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/annonc\/mdy518","article-title":"Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study","volume":"30","author":"Adams","year":"2019","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105111_bib2","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/annonc\/mdy517","article-title":"Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study","volume":"30","author":"Adams","year":"2019","journal-title":"Ann. Oncol."},{"issue":"20","key":"10.1016\/j.critrevonc.2025.105111_bib3","doi-asserted-by":"crossref","first-page":"5456","DOI":"10.1158\/1078-0432.CCR-20-1303","article-title":"PD-L1 protein expression on both tumor cells and macrophages are associated with response to neoadjuvant durvalumab with chemotherapy in triple-negative breast cancer","volume":"26","author":"Ahmed","year":"2020","journal-title":"Clin. Cancer Res"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105111_bib4","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/annonc\/mdu191","article-title":"Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients","volume":"25","author":"Ali","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105111_bib5","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/2584243","article-title":"Mast cell, the neglected member of the tumor microenvironment: role in breast cancer","volume":"2018","author":"Aponte-L\u00f3pez","year":"2018","journal-title":"J. Immunol. Res."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105111_bib6","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1016\/j.cell.2022.03.033","article-title":"Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche","volume":"185","author":"Baldominos","year":"2022","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105111_bib7","doi-asserted-by":"crossref","first-page":"5150","DOI":"10.1038\/s41467-018-07582-3","article-title":"Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing","volume":"9","author":"Bartoschek","year":"2018","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105111_bib8","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41591-021-01323-8","article-title":"A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer","volume":"27","author":"Bassez","year":"2021","journal-title":"Nat. Med"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105111_bib9","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/s41580-023-00615-w","article-title":"The technological landscape and applications of single-cell multi-omics","volume":"24","author":"Baysoy","year":"2023","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105111_bib10","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw192","article-title":"Relevance of tumor-infiltrating immune cell composition and functionality for disease outcome in breast cancer","volume":"109","author":"Bense","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105111_bib11","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1097\/CAD.0000000000000653","article-title":"DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy","volume":"29","author":"Bernier","year":"2018","journal-title":"Anticancer Drugs"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105111_bib12","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.trecan.2024.06.003","article-title":"Next-generation cancer vaccines and emerging immunotherapy combinations","volume":"10","author":"Brandenburg","year":"2024","journal-title":"Trends Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105111_bib13","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41592-019-0667-5","article-title":"NicheNet: modeling intercellular communication by linking ligands to target genes","volume":"17","author":"Browaeys","year":"2020","journal-title":"Nat. Methods"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105111_bib14","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1158\/1078-0432.CCR-14-0432","article-title":"Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer","volume":"21","author":"Burstein","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"6409","key":"10.1016\/j.critrevonc.2025.105111_bib15","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1126\/science.aau0730","article-title":"Joint profiling of chromatin accessibility and gene expression in thousands of single cells","volume":"361","author":"Cao","year":"2018","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105111_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/cells9081785","article-title":"Role of tumor-associated myeloid cells in breast cancer","volume":"9","author":"Cha","year":"2020","journal-title":"Cells"},{"issue":"6233","key":"10.1016\/j.critrevonc.2025.105111_bib17","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaa6090","article-title":"RNA imaging. Spatially resolved, highly multiplexed RNA profiling in single cells","volume":"348","author":"Chen","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2025.105111_bib18","article-title":"Single-cell ligand-receptor profiling reveals an immunotherapy-responsive subtype and prognostic signature in triple-negative breast cancer","volume":"16","author":"Chen","year":"2025","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105111_bib19","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41392-023-01452-1","article-title":"Macrophages in immunoregulation and therapeutics","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105111_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-008864","article-title":"Novel insights into paclitaxel's role on tumor-associated macrophages in enhancing PD-1 blockade in breast cancer treatment","volume":"12","author":"Choi","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2025.105111_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15081","article-title":"Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer","volume":"8","author":"Chung","year":"2017","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105111_bib22","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1038\/s41467-023-39762-1","article-title":"Cancer-associated fibroblast classification in single-cell and spatial proteomics data","volume":"14","author":"Cords","year":"2023","journal-title":"Nat. Commun."},{"issue":"10265","key":"10.1016\/j.critrevonc.2025.105111_bib23","first-page":"1817","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised","volume":"396","author":"Cortes","year":"2020","journal-title":"Place. Control. DoubleBlind Ph. 3 Clin. Trial Lancet"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105111_bib24","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1038\/s41467-024-47068-z","article-title":"Deciphering the spatial landscape and plasticity of immunosuppressive fibroblasts in breast cancer","volume":"15","author":"Croizer","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2025.105111_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1172681","article-title":"Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy","volume":"14","author":"Das","year":"2023","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105111_bib26","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10549-020-05936-4","article-title":"Serial single-cell profiling analysis of metastatic TNBC during Nab-paclitaxel and pembrolizumab treatment","volume":"185","author":"Deng","year":"2021","journal-title":"Breast Cancer Res. Treat."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105111_bib27","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/cac2.12429","article-title":"Single-cell atlas reveals a distinct immune profile fostered by T cell-B cell crosstalk in triple negative breast cancer","volume":"43","author":"Ding","year":"2023","journal-title":"Cancer Commun."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105111_bib28","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s12032-025-02808-z","article-title":"Emerging frontiers in adoptive cell therapies: innovations, challenges, and future perspectives","volume":"42","author":"Dogra","year":"2025","journal-title":"Med Oncol."},{"key":"10.1016\/j.critrevonc.2025.105111_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.715234","article-title":"CD8(+) T cell exhaustion in cancer","volume":"12","author":"Dolina","year":"2021","journal-title":"Front Immunol."},{"key":"10.1016\/j.critrevonc.2025.105111_bib30","article-title":"Decoding the hypoxic tumor microenvironment in colorectal cancer for prognostic modeling and therapeutic target discovery","volume":"16","author":"Duan","year":"2025","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105111_bib31","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jamaoncol.2018.4224","article-title":"Long-term clinical outcomes and biomarker analyses of Atezolizumab therapy for patients with metastatic triple-negative breast cancer: a Phase 1 study","volume":"5","author":"Emens","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2025.105111_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2023.01.001","article-title":"Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer - a single-arm phase II trial (NeoImmunoboost, AGO-B-041)","volume":"184","author":"Fasching","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.105111_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.105003","article-title":"Beyond monospecificity: the modular revolution of bispecific immunotherapeutics","volume":"216","author":"Fattahi","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2025.105111_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104437","article-title":"Expanding horizons in cancer therapy by immunoconjugates targeting tumor microenvironments","volume":"201","author":"Fattahi","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105111_bib35","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrc.2016.97","article-title":"Engineered T cells: the promise and challenges of cancer immunotherapy","volume":"16","author":"Fesnak","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"13","key":"10.1016\/j.critrevonc.2025.105111_bib36","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1084\/jem.20121015","article-title":"Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice","volume":"209","author":"Frebel","year":"2012","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105111_bib37","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","article-title":"Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment","volume":"9","author":"Garrido-Castro","year":"2019","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105111_bib38","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.annonc.2022.02.004","article-title":"Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study","volume":"33","author":"Gianni","year":"2022","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105111_bib39","doi-asserted-by":"crossref","first-page":"5694","DOI":"10.1038\/s41467-024-49916-4","article-title":"Single-cell resolution characterization of myeloid-derived cell states with implication in cancer outcome","volume":"15","author":"Guimar\u00e3es","year":"2024","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105111_bib40","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1038\/s41587-022-01483-z","article-title":"High-plex imaging of RNA and proteins at subcellular resolution in fixed tissue by spatial molecular imaging","volume":"40","author":"He","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.critrevonc.2025.105111_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102700","article-title":"Neoadjuvant anthracycline followed by toripalimab combined with nab-paclitaxel in patients with early triple-negative breast cancer (NeoTENNIS): a single-arm, phase II study","volume":"74","author":"He","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.critrevonc.2025.105111_bib42","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-079603","article-title":"Intensive chemotherapy versus standard chemotherapy among patients with high risk, operable, triple negative breast cancer based on integrated mRNA-lncRNA signature (BCTOP-T-A01): randomised, multicentre, phase 3 trial","volume":"387","author":"He","year":"2024","journal-title":"Bmj"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105111_bib43","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41422-022-00627-9","article-title":"Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response","volume":"32","author":"He","year":"2022","journal-title":"Cell Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105111_bib44","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/cncr.32599","article-title":"A phase 2 clinical trial\u00a0assessing the\u00a0efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer","volume":"126","author":"Ho","year":"2020","journal-title":"Cancer"},{"issue":"36","key":"10.1016\/j.critrevonc.2025.105111_bib45","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1200\/JCO.24.00003","article-title":"PEARL: a Phase Ib\/II biomarker study of adding radiation therapy to pembrolizumab before neoadjuvant chemotherapy in human epidermal growth factor receptor 2-negative breast cancer","volume":"42","author":"Ho","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105111_bib46","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.cell.2019.10.028","article-title":"B cells and T follicular helper cells mediate response to checkpoint inhibitors in high mutation burden mouse models of breast cancer","volume":"179","author":"Hollern","year":"2019","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105111_bib47","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1038\/s41467-025-58874-4","article-title":"Deconvolution of cell types and states in spatial multiomics utilizing TACIT","volume":"16","author":"Huynh","year":"2025","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105111_bib48","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1158\/1078-0432.CCR-24-2172","article-title":"Phase I study of ROR1-specific CAR-T cells in advanced hematopoietic and epithelial malignancies","volume":"31","author":"Jaeger-Ruckstuhl","year":"2025","journal-title":"Clin. Cancer Res"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105111_bib49","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.1172\/JCI96268","article-title":"Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy","volume":"128","author":"Jayaprakash","year":"2018","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.critrevonc.2025.105111_bib50","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-24-3283","article-title":"Proliferation of tumor-related regulatory T cells in circulation dictates efficacy of chemoimmunotherapy in triple-negative breast cancer","author":"Jeon","year":"2025","journal-title":"Clin. Cancer Res"},{"issue":"17_","key":"10.1016\/j.critrevonc.2025.105111_bib51","doi-asserted-by":"crossref","first-page":"LBA1013","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA1013","article-title":"TORCHLIGHT: a randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC)","volume":"41","author":"Jiang","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105111_bib52","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105111_bib53","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1038\/s41467-018-06052-0","article-title":"Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq","volume":"9","author":"Karaayvaz","year":"2018","journal-title":"Nat. Commun."},{"issue":"7764","key":"10.1016\/j.critrevonc.2025.105111_bib54","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","article-title":"TOX transcriptionally and epigenetically programs CD8(+) T cell exhaustion","volume":"571","author":"Khan","year":"2019","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105111_bib55","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines10060943","article-title":"Exploring the impact of TREM2 in tumor-associated macrophages","volume":"10","author":"Khantakova","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.critrevonc.2025.105111_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113386","article-title":"Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: a phase IB\/II study (KCSG BR18-16)","volume":"195","author":"Kim","year":"2023","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105111_bib57","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.cell.2015.04.044","article-title":"Droplet barcoding for single-cell transcriptomics applied to embryonic stem cells","volume":"161","author":"Klein","year":"2015","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105111_bib58","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1080\/21645515.2016.1199310","article-title":"Pembrolizumab (Keytruda)","volume":"12","author":"Kwok","year":"2016","journal-title":"Hum. Vaccin Immunother."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105111_bib59","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1073\/pnas.1115166109","article-title":"Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine","volume":"109","author":"Lakshminarayanan","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105111_bib60","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J. Clin. Invest"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105111_bib61","doi-asserted-by":"crossref","first-page":"6276","DOI":"10.1038\/s41467-021-26502-6","article-title":"Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes","volume":"12","author":"Lehmann","year":"2021","journal-title":"Nat. Commun."},{"issue":"26","key":"10.1016\/j.critrevonc.2025.105111_bib62","doi-asserted-by":"crossref","first-page":"5719","DOI":"10.1016\/j.cell.2023.11.001","article-title":"Choroid plexus mast cells drive tumor-associated hydrocephalus","volume":"186","author":"Li","year":"2023","journal-title":"Cell"},{"issue":"14","key":"10.1016\/j.critrevonc.2025.105111_bib63","article-title":"Improved efficacy of triple-negative breast cancer immunotherapy via hydrogel-based co-delivery of CAR-T cells and mitophagy agonist","volume":"12","author":"Li","year":"2025","journal-title":"Adv. Sci. (Weinh. )"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105111_bib64","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/s41467-024-45160-y","article-title":"The anti-PD-L1\/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial","volume":"15","author":"Li","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105111_bib65","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41746-024-01043-6","article-title":"Informing immunotherapy with multi-omics driven machine learning","volume":"7","author":"Li","year":"2024","journal-title":"NPJ Digit Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105111_bib66","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ccell.2021.11.002","article-title":"The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1","volume":"40","author":"Li","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2025.105111_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2024.108537","article-title":"Proteomic, single-cell and bulk transcriptomic analysis of plasma and tumor tissues unveil core proteins in response to anti-PD-L1 immunotherapy in triple negative breast cancer","volume":"176","author":"Li","year":"2024","journal-title":"Comput. Biol. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105111_bib68","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","article-title":"Recent advances in therapeutic strategies for triple-negative breast cancer","volume":"15","author":"Li","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105111_bib69","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1053\/j.seminoncol.2015.05.013","article-title":"Antagonists of PD-1 and PD-L1 in cancer treatment","volume":"42","author":"Lipson","year":"2015","journal-title":"Semin Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105111_bib70","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12943-023-01850-7","article-title":"Advances in immunotherapy for triple-negative breast cancer","volume":"22","author":"Liu","year":"2023","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105111_bib71","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ymthe.2017.10.020","article-title":"Combination immunotherapy of MUC1 mRNA nano-vaccine and CTLA-4 blockade effectively inhibits growth of triple negative breast cancer","volume":"26","author":"Liu","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2025.105111_bib72","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1146\/annurev-pathmechdis-012418-012718","article-title":"Diversity, mechanisms, and significance of macrophage plasticity","volume":"15","author":"Locati","year":"2020","journal-title":"Annu Rev. Pathol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105111_bib73","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1200\/JCO.2011.41.0902","article-title":"Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98","volume":"31","author":"Loi","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105111_bib74","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.cell.2015.05.002","article-title":"Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets","volume":"161","author":"Macosko","year":"2015","journal-title":"Cell"},{"issue":"20","key":"10.1016\/j.critrevonc.2025.105111_bib75","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1016\/j.cell.2023.08.039","article-title":"Single-cell atlas reveals correlates of high cognitive function, dementia, and resilience to Alzheimer's disease pathology","volume":"186","author":"Mathys","year":"2023","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105111_bib76","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","article-title":"Clonal heterogeneity and tumor evolution: past, present, and the future","volume":"168","author":"McGranahan","year":"2017","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105111_bib77","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12123529","article-title":"Current progresses and challenges of immunotherapy in triple-negative breast cancer","volume":"12","author":"Mediratta","year":"2020","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105111_bib78","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","article-title":"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer","volume":"32","author":"Miles","year":"2021","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105111_bib79","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1093\/annonc\/mdw150","article-title":"Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence","volume":"27","author":"Mittendorf","year":"2016","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105111_bib80","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","article-title":"PD-L1 expression in triple-negative breast cancer","volume":"2","author":"Mittendorf","year":"2014","journal-title":"Cancer Immunol. Res."},{"issue":"17","key":"10.1016\/j.critrevonc.2025.105111_bib81","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26178448","article-title":"Enhancing antitumor efficacy of MUC1 mRNA nano-vaccine by CTLA-4 siRNA-mediated immune checkpoint modulation in triple negative breast cancer mice model","volume":"26","author":"Monfaredan","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"21","key":"10.1016\/j.critrevonc.2025.105111_bib82","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2015.64.8931","article-title":"Pembrolizumab in patients with advanced triple-negative breast cancer: Phase Ib KEYNOTE-012 study","volume":"34","author":"Nanda","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105111_bib83","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1038\/s41591-024-03249-3","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial","volume":"30","author":"Nederlof","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2025.105111_bib84","doi-asserted-by":"crossref","first-page":"23","DOI":"10.21037\/tbcr-24-4","article-title":"Toripalimab: a new torchlight illuminating the path for metastatic triple negative breast cancer?","volume":"5","author":"Park","year":"2024","journal-title":"Transl. Breast Cancer Res."},{"issue":"7669","key":"10.1016\/j.critrevonc.2025.105111_bib85","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature23477","article-title":"Identification of essential genes for cancer immunotherapy","volume":"548","author":"Patel","year":"2017","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105111_bib86","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12943-019-1055-6","article-title":"Neoantigen vaccine: an emerging tumor immunotherapy","volume":"18","author":"Peng","year":"2019","journal-title":"Mol. Cancer"},{"issue":"21","key":"10.1016\/j.critrevonc.2025.105111_bib87","doi-asserted-by":"crossref","first-page":"6365","DOI":"10.7150\/jca.46301","article-title":"Identification of CTLA-4 associated with tumor microenvironment and competing interactions in triple negative breast cancer by co-expression network analysis","volume":"11","author":"Peng","year":"2020","journal-title":"J. Cancer"},{"issue":"7974","key":"10.1016\/j.critrevonc.2025.105111_bib88","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/s41586-023-06188-0","article-title":"Mast cells link immune sensing to antigen-avoidance behaviour","volume":"620","author":"Plum","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2025.105111_bib89","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.3389\/fimmu.2019.02298","article-title":"The diverse function of PD-1\/PD-L pathway beyond cancer","volume":"10","author":"Qin","year":"2019","journal-title":"Front Immunol."},{"issue":"6029","key":"10.1016\/j.critrevonc.2025.105111_bib90","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1126\/science.1202947","article-title":"Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4","volume":"332","author":"Qureshi","year":"2011","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105111_bib91","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24109038","article-title":"Next generation CD44v6-specific CAR-NK cells effective against triple negative breast cancer","volume":"24","author":"Raftery","year":"2023","journal-title":"Int J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105111_bib92","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s10549-007-9546-3","article-title":"Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases","volume":"107","author":"Rajput","year":"2008","journal-title":"Breast Cancer Res. Treat."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105111_bib93","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1158\/2326-6066.CIR-18-0619","article-title":"Poor response to neoadjuvant chemotherapy correlates with mast cell infiltration in inflammatory breast cancer","volume":"7","author":"Reddy","year":"2019","journal-title":"Cancer Immunol. Res"},{"key":"10.1016\/j.critrevonc.2025.105111_bib94","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.818693","article-title":"Comprehensive analysis of the immunogenomics of triple-negative breast cancer brain metastases from LCCC1419","volume":"12","author":"Routh","year":"2022","journal-title":"Front Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105111_bib95","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","article-title":"CTLA-4: a moving target in immunotherapy","volume":"131","author":"Rowshanravan","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105111_bib96","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41587-019-0071-9","article-title":"A comparison of single-cell trajectory inference methods","volume":"37","author":"Saelens","year":"2019","journal-title":"Nat. Biotechnol."},{"issue":"23","key":"10.1016\/j.critrevonc.2025.105111_bib97","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14235936","article-title":"Trop-2 as a therapeutic target in breast cancer","volume":"14","author":"Sakach","year":"2022","journal-title":"Cancers"},{"issue":"7868","key":"10.1016\/j.critrevonc.2025.105111_bib98","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41586-021-03648-3","article-title":"Clonal fitness inferred from time-series modelling of single-cell cancer genomes","volume":"595","author":"Salehi","year":"2021","journal-title":"Nature"},{"issue":"14","key":"10.1016\/j.critrevonc.2025.105111_bib99","doi-asserted-by":"crossref","first-page":"8845","DOI":"10.1093\/nar\/gku555","article-title":"Single-cell RNA-seq: advances and future challenges","volume":"42","author":"Saliba","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.critrevonc.2025.105111_bib100","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-025-00873-1","article-title":"Biomarker prediction of immunotherapy response in breast cancer: from single markers to multi-omics integration","author":"Sanjari Moghaddam","year":"2025","journal-title":"NPJ Breast Cancer"},{"issue":"22","key":"10.1016\/j.critrevonc.2025.105111_bib101","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and Nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.critrevonc.2025.105111_bib102","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall survival with pembrolizumab in early-stage triple-negative breast cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105111_bib103","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"13_ement","key":"10.1016\/j.critrevonc.2025.105111_bib104","doi-asserted-by":"crossref","first-page":"CT049","DOI":"10.1158\/1538-7445.AM2019-CT049","article-title":"Abstract CT049: Phase Ib study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced\/metastatic triple-negative breast cancer (TNBC)","volume":"79","author":"Schmid","year":"2019","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105111_bib105","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","article-title":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Schmid","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.105111_bib106","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1146\/annurev.immunol.21.120601.141110","article-title":"T cell anergy","volume":"21","author":"Schwartz","year":"2003","journal-title":"Annu Rev. Immunol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105111_bib107","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1158\/2767-9764.CRC-22-0486","article-title":"Phase I trial of autologous RNA-electroporated cMET-directed CAR T cells administered intravenously in patients with melanoma and breast carcinoma","volume":"3","author":"Shah","year":"2023","journal-title":"Cancer Res Commun."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105111_bib108","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1182\/blood.V96.9.3094","article-title":"Impaired function of circulating HIV-specific CD8(+) T cells in chronic human immunodeficiency virus infection","volume":"96","author":"Shankar","year":"2000","journal-title":"Blood"},{"issue":"7983","key":"10.1016\/j.critrevonc.2025.105111_bib109","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41586-023-06569-5","article-title":"Spatial atlas of the mouse central nervous system at molecular resolution","volume":"622","author":"Shi","year":"2023","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105111_bib110","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ccell.2023.12.012","article-title":"Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer","volume":"42","author":"Shiao","year":"2024","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105111_bib111","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","article-title":"Intratumoral Tcf1(+)PD-1(+)CD8(+) T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy","volume":"50","author":"Siddiqui","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.critrevonc.2025.105111_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108253","article-title":"Triple negative breast cancer (TNBC): non-genetic tumor heterogeneity and immune microenvironment: emerging treatment options","volume":"237","author":"So","year":"2022","journal-title":"Pharm. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105111_bib113","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1186\/s12967-025-07105-x","article-title":"A novel anti-PD-L1\/IL-8 bispecific antibody BP2402 enhances antitumor immunity and modulates inflammatory signaling in triple-negative breast cancer mice model","volume":"23","author":"Song","year":"2025","journal-title":"J. Transl. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105111_bib114","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41587-020-0739-1","article-title":"Highly sensitive spatial transcriptomics at near-cellular resolution with Slide-seqV2","volume":"39","author":"Stickels","year":"2021","journal-title":"Nat. Biotechnol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105111_bib115","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/nmeth.4380","article-title":"Simultaneous epitope and transcriptome measurement in single cells","volume":"14","author":"Stoeckius","year":"2017","journal-title":"Nat. Methods"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105111_bib116","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s40364-025-00743-9","article-title":"Correction: MORF4L2 induces immunosuppressive microenvironment and immunotherapy resistance through GRHL2\/MORF4L2\/H4K12Ac\/CSF1 axis in triple-negative breast cancer","volume":"13","author":"Sui","year":"2025","journal-title":"Biomark. Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105111_bib117","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nmeth.1315","article-title":"mRNA-Seq whole-transcriptome analysis of a single cell","volume":"6","author":"Tang","year":"2009","journal-title":"Nat. Methods"},{"key":"10.1016\/j.critrevonc.2025.105111_bib118","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13578-019-0314-y","article-title":"The single-cell sequencing: new developments and medical applications","volume":"9","author":"Tang","year":"2019","journal-title":"Cell Biosci."},{"issue":"686","key":"10.1016\/j.critrevonc.2025.105111_bib119","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abl4414","article-title":"Immature natural killer cells promote progression of triple-negative breast cancer","volume":"15","author":"Thacker","year":"2023","journal-title":"Sci. Transl. Med"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105111_bib120","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","article-title":"T cell dysfunction in cancer","volume":"33","author":"Thommen","year":"2018","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105111_bib121","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S1074-7613(00)80366-0","article-title":"The emerging role of CTLA-4 as an immune attenuator","volume":"7","author":"Thompson","year":"1997","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105111_bib122","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The immune landscape of cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"issue":"18","key":"10.1016\/j.critrevonc.2025.105111_bib123","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1158\/0008-5472.CAN-22-1427","article-title":"Lipid-associated macrophages are induced by cancer-associated fibroblasts and mediate immune suppression in breast cancer","volume":"82","author":"Timperi","year":"2022","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105111_bib124","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1208\/s12248-021-00574-0","article-title":"Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics","volume":"23","author":"Twomey","year":"2021","journal-title":"Aaps J."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105111_bib125","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/2159-8290.CD-24-0684","article-title":"AAnet resolves a continuum of spatially localized cell states to unveil intratumoral heterogeneity","volume":"15","author":"Venkat","year":"2025","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105111_bib126","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.ccell.2023.01.004","article-title":"Intratumoral CD8(+) T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer","volume":"41","author":"Virassamy","year":"2023","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105111_bib127","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41591-019-0432-4","article-title":"Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial","volume":"25","author":"Voorwerk","year":"2019","journal-title":"Nat. Med"},{"key":"10.1016\/j.critrevonc.2025.105111_bib128","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3389\/fimmu.2020.00176","article-title":"Adoptive cell therapy targeting neoantigens: a frontier for cancer research","volume":"11","author":"Wang","year":"2020","journal-title":"Front Immunol."},{"key":"10.1016\/j.critrevonc.2025.105111_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2025.102351","article-title":"Mechanisms of radioresistance and radiosensitization strategies for triple negative breast cancer","volume":"55","author":"Wang","year":"2025","journal-title":"Transl. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105111_bib130","article-title":"Spatial transcriptomics reveals substantial heterogeneity in triple-negative breast cancer with potential clinical implications","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"issue":"365","key":"10.1016\/j.critrevonc.2025.105111_bib131","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag1093","article-title":"The synthetic diazonamide DZ-2384 has distinct effects on microtubule curvature and dynamics without neurotoxicity","volume":"8","author":"Wieczorek","year":"2016","journal-title":"Sci. Transl. Med."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105111_bib132","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/s41588-021-00911-1","article-title":"A single-cell and spatially resolved atlas of human breast cancers","volume":"53","author":"Wu","year":"2021","journal-title":"Nat. Genet."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105111_bib133","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1038\/s41591-025-03776-7","article-title":"Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial","volume":"31","author":"Wu","year":"2025","journal-title":"Nat. Med."},{"issue":"19","key":"10.1016\/j.critrevonc.2025.105111_bib134","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2019104063","article-title":"Stromal cell diversity associated with immune evasion in human triple-negative breast cancer","volume":"39","author":"Wu","year":"2020","journal-title":"Embo J."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105111_bib135","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/hmg\/ddab042","article-title":"Integrative analyses of scRNA-seq and scATAC-seq reveal CXCL14 as a key regulator of lymph node metastasis in breast cancer","volume":"30","author":"Xu","year":"2021","journal-title":"Hum. Mol. Genet."},{"issue":"14","key":"10.1016\/j.critrevonc.2025.105111_bib136","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1158\/0008-5472.CAN-15-2973","article-title":"FAP promotes immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3-CCL2 signaling","volume":"76","author":"Yang","year":"2016","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105111_bib137","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12943-023-01805-y","article-title":"Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer","volume":"22","author":"Ye","year":"2023","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105111_bib138","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1631\/jzus.B2300492","article-title":"Immune checkpoint blockade for cancer therapy: current progress and perspectives","volume":"26","author":"Ye","year":"2025","journal-title":"J. Zhejiang Univ. Sci. B"},{"key":"10.1016\/j.critrevonc.2025.105111_bib139","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115685","article-title":"Immune cell transcriptional profiles from pre-vaccination peripheral blood predict immune response to preventative MUC1 cancer vaccine","volume":"228","author":"Yuan","year":"2025","journal-title":"Eur. J. Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105111_bib140","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1158\/1078-0432.CCR-15-1849","article-title":"Reversing T-cell dysfunction and exhaustion in cancer","volume":"22","author":"Zarour","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105111_bib141","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S1470-2045(24)00757-5","article-title":"Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902\/IBCSG 61-20; Neo-N): a non-comparative, open-label, randomised, phase 2 trial","volume":"26","author":"Zdenkowski","year":"2025","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105111_bib142","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ijrobp.2012.12.025","article-title":"Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas","volume":"86","author":"Zeng","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105111_bib143","article-title":"ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth","volume":"7","author":"Zhang","year":"2012","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105111_bib144","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.ccell.2021.09.010","article-title":"Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer","volume":"39","author":"Zhang","year":"2021","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105111_bib145","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ccell.2025.01.007","article-title":"Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer","volume":"43","author":"Zhang","year":"2025","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105111_bib146","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13073-024-01388-3","article-title":"Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients","volume":"16","author":"Zhang","year":"2024","journal-title":"Genome Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105111_bib147","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1158\/2326-6066.CIR-16-0264","article-title":"Breast cancer neoantigens can induce CD8(+) T-cell responses and antitumor immunity","volume":"5","author":"Zhang","year":"2017","journal-title":"Cancer Immunol. Res."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105111_bib148","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1038\/s41591-022-01799-y","article-title":"A T cell resilience model associated with response to immunotherapy in multiple tumor types","volume":"28","author":"Zhang","year":"2022","journal-title":"Nat. Med"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105111_bib149","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41551-024-01285-5","article-title":"Antitumour vaccination via the targeted proteolysis of antigens isolated from tumour lysates","volume":"9","author":"Zhao","year":"2025","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.critrevonc.2025.105111_bib150","article-title":"Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer","volume":"14","author":"Zheng","year":"2023","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105111_bib151","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s12282-024-01543-z","article-title":"Neoadjuvant nivolumab plus bevacizumab therapy improves the prognosis of triple-negative breast cancer in humanized mouse models","volume":"31","author":"Zheng","year":"2024","journal-title":"Breast Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105111_bib152","doi-asserted-by":"crossref","first-page":"6584","DOI":"10.1038\/s41467-025-61034-3","article-title":"Integrative spatial omics reveals distinct tumor-promoting multicellular niches and immunosuppressive mechanisms in Black American and White American patients with TNBC","volume":"16","author":"Zhu","year":"2025","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105111_bib153","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188593","article-title":"Progress and challenges of immunotherapy in triple-negative breast cancer","volume":"1876","author":"Zhu","year":"2021","journal-title":"Biochim Biophys. Acta Rev. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105111_bib154","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.molcel.2017.01.023","article-title":"Comparative analysis of single-cell RNA sequencing methods","volume":"65","author":"Ziegenhain","year":"2017","journal-title":"Mol. Cell"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825004998?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825004998?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T02:28:41Z","timestamp":1773973721000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825004998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":154,"alternative-id":["S1040842825004998"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105111","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Research progress on immunotherapeutics for triple-negative breast cancer from a single-cell perspective","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105111","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105111"}}